SCHEMBL31067231

SCHEMBL31067231

CC1(c2cccc(F)c2)CCc2[nH]c(=O)[nH]c(=O)c2C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.36
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
F9 P00740 3/20 0.34
GSK3A P49840 3/20 0.34
GSK3B P49841 3/20 0.34
SLC6A4 P31645 3/20 0.33
SLC6A3 Q01959 3/20 0.33
SLC6A2 P23975 2/20 0.33
HSD11B1 P28845 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
CHRNA1 P02708 1/20 0.33
CHRNB1 P11230 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
OPRM1 P35372 1/20 0.32
OGFRL1 Q5TC84 1/20 0.32
KDM1A O60341 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31067234 0.84 ALDH1A1 (0.40) PARP1ALDH1A1MAPTHSD11B1OPRM1
SCHEMBL31067218 0.72 MEN1 (0.43) GSK3AGSK3BSLC6A4SLC6A3SLC6A2
SCHEMBL17033038 0.68 KDM1A (0.50) SLC6A4SLC6A3SLC6A2HSD11B1HCAR2
Ammonia Solution, Strong SCHEMBL28903694 0.67 KDM1A (0.48) SLC6A4SLC6A3SLC6A2HSD11B1HCAR2
SCHEMBL31067185 0.66 SLC6A4 (0.33) F9SLC6A4SLC6A3SLC6A2HSD11B1
SCHEMBL31067141 0.66 SLC6A4 (0.33) F9SLC6A4SLC6A3SLC6A2HSD11B1
SCHEMBL31067131 0.66 SLC6A4 (0.33) F9SLC6A4SLC6A3SLC6A2HSD11B1
SCHEMBL12203836 0.66 SLC6A4 (0.54) SLC6A4SLC6A3SLC6A2HCAR2CHRNA1
SCHEMBL257282 0.66 SLC6A4 (0.50) SLC6A4SLC6A3SLC6A2HSD11B1HCAR2
SCHEMBL31067175 0.65 MAPK1 (0.44) PARP1ALDH1A1MAPTHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026047575-A1 HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER NOVARTIS AG (CH) 2026-03-05 WO disclosed
EP-4673431-A1 HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER Novartis AG (CH) 2026-01-07 EP disclosed
US-12129246-B1 Hydroquinazoline derivatives for the treatment of a disease or disorder NOVARTIS AG (CH) 2024-10-29 US disclosed
US-20240336598-A1 HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2024-10-10 US disclosed
WO-2024180499-A1 HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER NOVARTIS AG (CH) 2024-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129246-B1 Hydroquinazoline derivatives for the treatment of a disease or disorder RECQL, NRAS, RAB1A PARP1 2486/4885ALDH1A1 810/4885MAPT 2473/4885
US-20240336598-A1 HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER RECQL, NRAS, RAB1A PARP1 2486/4885ALDH1A1 810/4885MAPT 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.